Hikma Pharmaceuticals Plc. announced yesterday that it has reached a licensing agreement with Republic of Korea-based Celltrion for its rituximab biosimilar, Truxima, referenced on MabThera.
Hikma Pharmaceuticals Plc. announced yesterday that it has reached a licensing agreement with Republic of Korea-based Celltrion for its rituximab biosimilar, Truxima, referenced on MabThera. Hikma, based in Jordan, now has exclusive rights from Celltrion to market 3 biosimilar products, rituximab (Truxima), infliximab (Remsima), and trastuzumab (Herzuma) in all of the Middle East and North African (MENA) markets.
Truxima was the first biosimilar anticancer therapeutic to hit the European market in February 2017. Truxima, like the reference rituximab, which is sold in the European Union as MabThera (and as Rituxan in the United States), is used to treat patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and microscopic polyangiitis, among other indications.
Mazen Darwazah, vice chairman and CEO of MENA and Emerging Markets said, “We are pleased to be adding Truxima to our biosimilar and oncology portfolio, building on the success of our partners with Celltrion in the MENA region. Global partnerships are an integral part of our strategy to enhance our portfolio in key therapeutic areas and increase patients’ access to high-quality, affordable medicines.”
The Jordan-based company boasts a product portfolio of over 700 products across key therapeutic areas. Hikma makes and markets branded and non-branded generic and injectable drugs in more than 50 different countries. Yet the company has been hit by higher pricing pressures in the generic industry, and has lowered revenue forecasts 3 times this year alone.
Hikma is also currently in a dispute with the FDA over plans to launch a generic copy of GlaxoSmithKline’s popular drug Advair in the United States. The root of the issue is the team’s clinical endpoint study, according to Hikma, which says it “firmly” disagrees with the FDA’s concerns. With Hikma in a potentially lengthy delay, Novartis’ Sandoz could be the uncontested first-place winner in the race to bring a generic of the respiratory blockbuster to the market.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.